Document is current
Any future updates will be listed below
-
Authors
Schuler, Martin https://orcid.org/0000-0002-2166-3394
Cuppens, Kristof https://orcid.org/0000-0002-8153-0008
Plönes, Till
Wiesweg, Marcel https://orcid.org/0000-0002-9698-9559
Du Pont, Bert
Hegedus, Balazs
Köster, Johannes https://orcid.org/0000-0001-9818-9320
Mairinger, Fabian
Darwiche, Kaid https://orcid.org/0000-0003-0681-1325
Paschen, Annette https://orcid.org/0000-0003-1651-1262
Maes, Brigitte https://orcid.org/0009-0004-2301-3370
Vanbockrijck, Michel
Lähnemann, David https://orcid.org/0000-0002-9138-4112
Zhao, Fang https://orcid.org/0000-0002-2746-9242
Hautzel, Hubertus https://orcid.org/0000-0002-3581-5264
Theegarten, Dirk
Hartemink, Koen
Reis, Henning
Baas, Paul https://orcid.org/0000-0001-7018-9556
Schramm, Alexander https://orcid.org/0000-0001-7670-7529
Aigner, Clemens https://orcid.org/0000-0002-7787-991X
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb (CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063, CA224-063)
Bristol Myers Squibb
- License Information
-
More Information
Article History
Received: 29 November 2023
Accepted: 2 April 2024
First Online: 30 April 2024
Competing interests
: M.S., K.C., B.H., J.K., F.M., A.P., B.M., H.R., P.B., A.S. and C.A. received institutional funding, paid to the University Hospital Essen, from Bristol Myers Squibb to support the study NEOpredict-Lung. The following authors declare potential conflicts of interest: M.S. (Fees for consulting from Amgen, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Janssen, MSD, Novartis, Roche, Sanofi and Tacalyx; honoraria for CME presentations from Amgen, Bristol Myers Squibb, GSK, Janssen, MSD, Roche and Sanofi; institutional research funding to University Hospital Essen from AstraZeneca, Bristol Myers Squibb and Janssen); K.C. (Fees for consulting from AstraZeneca/Medimmune, Bayer, Bristol Myers Squibb, MSD; institutional research funding from Bristol Myers Squibb; travel support from MSD; other relationship to Bristol Myers Squibb); M.W. (Fees for consulting from Daiichi Sankyo, Janssen, Novartis, Pfizer and Roche; honoraria for CME presentations from Amgen, AstraZeneca, GSK, Janssen, Novartis, Roche and Takeda; institutional research funding to University Hospital Essen from Bristol Myers Squibb and Takeda; travel support from Amgen and Bristol Myers Squibb), B.H. (institutional research funding to University Hospital Essen from Bristol Myers Squibb), K.D. (Fees for consulting from bess, Boehringer Ingelheim, Boston Scientific, Broncus Medical, FreeFlow, Fujifilm, Lys Medical, Medtronic, Morair Medtech, Olympus, Pulmonx and Storz; honoraria for CME presentations from AstraZeneca, Boehringer Ingelheim, Boston Scientific, Broncus Medical, Erbe Elektromedizin, Olympus and Storz; institutional research funding to University Medicine Essen – Ruhrlandklinik from Ambu, Broncus Medical, Epigenomics, Gala Therapeutics, Novartis, Nuvaira, PneumRx, Pulmonx and Roche); H.H. (Honoraria for CME presentations from Urenco; travel support from Pari; institutional research funding to University Hospital Essen from Pari), H.R. (Honoraria for CME presentations from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Chop GmbH, Diaceutics, GSK, HUeG, Janssen-Cilag, MCI, Merck, Novartis, Roche Pharma, Sanofi and Wolfsburg Klinikum; institutional research funding from Bristol Myers Squibb), P.B. (Fees for consulting from AstraZeneca, Beigene, Bristol Myers Squibb, Merck Sharp & Dohme; honoraria from Bristol Myers Squibb, MSD; research funding to the Netherlands Cancer Institute from Bristol Myers Squibb; travel support from MSD; other relationship to Bristol Myers Squibb), A.S. (Institutional research funding to University Hospital Essen from Bristol Myers Squibb) and C.A. (Fees for consulting from Ewimed; honoraria for CME presentations from AstraZeneca, Bristol Myers Squibb, Roche; institutional research funding to University Hospital Essen Bristol Myers Squibb, and to University Medicine Essen – Ruhrlandklinik from PharmaCept). The other authors declare no competing interests.
